Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. NextCure, Inc.
  6. Company
    NXTC   US65343E1082

NEXTCURE, INC.

(NXTC)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-31 pm EST
1.670 USD   +1.21%
2022NextCure, Inc.(NasdaqGS:NXTC) dropped from NASDAQ Biotechnology Index
CI
2022Transcript : NextCure, Inc. Presents at Bank of America 2022 Virtual Biotech SMID Cap Conference, Dec-08-2022 03:20 PM
CI
2022NextCure to Present at Upcoming Investor Conferences
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Business Summary
Logo NextCure, Inc.
NextCure, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel, immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Through its proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology (FIND-IO), platform, the Company is studying various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Its product candidates include NC318, NC410, NC762 and NC 525. NC318, is an immunomedicine against a novel immunomodulatory protein called Siglec-15. NC410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor. NC762, is an immunomedicine targeting an immunomodulatory molecule called human B7 homolog 4 protein. NC525, is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia.

Number of employees : 87 people.
Managers
Name Title Age Since
Michael S. Richman President, Chief Executive Officer & Director 61 2015
Dong-Sik Cho, Dr. Chief Executive Officer 60 2021
Steven P. Cobourn Chief Financial Officer 59 2018
Solomon Langermann, Dr. Senior Vice President-Research 62 2015
Han Myint, Dr. Chief Medical Officer 69 2021
Timothy Mayer, Dr. Vice President-Business Development 57 2016
Sebastien Maloveste, Dr. Vice President-Business Development - -
Sourav Kundu, Dr. Senior Vice President-Development & Manufacturing 62 2021
Members of the board
Name Title Age Since
David S. Kabakoff, Dr. Chairman 74 2015
Chau Quang Khuong Independent Director 46 2015
Elaine V. Jones, Dr. Independent Director 67 2015
Stephen W. Webster Independent Director 61 2019
Garry Allen Nicholson Independent Director 67 2020
John Houston Independent Director 62 2020
Ellen G. Feigal, Dr. Independent Director 67 2021
Anne E Borgman, Dr. Independent Director 54 2021
Michael S. Richman President, Chief Executive Officer & Director 61 2015
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 27,774,536 25,331,962 91.2% 0 0.0% 91.2%
Shareholders
NameEquities%
OrbiMed Advisors Private Equity 2,711,013 9.76%
Sofinnova Investments, Inc. 2,671,856 9.62%
Pfizer Inc. 1,970,759 7.10%
Lord, Abbett & Co. LLC 1,764,147 6.35%
Eli Lilly and Company 1,704,391 6.14%
K2 & Associates Investment Management, Inc. 1,581,311 5.69%
Millennium Management LLC 1,449,885 5.22%
Great Point Partners LLC 999,666 3.60%
Hillhouse Investment Management Ltd. (Hong Kong) 978,570 3.52%
The Vanguard Group, Inc. 903,098 3.25%
Company contact information
NextCure, Inc.
9000 Virginia Manor Road
Suite 200
Beltsville, MD 20705

Phone : +1.240.399.4900
Web : http://www.nextcure.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of NextCure, Inc.